Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 6, 2020 (6 years ago)

clomiPRAMINE Hydrochloride Capsules USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet/Capsule Specification

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

clomiPRAMINE Hydrochloride Capsules USP, 50 mg, 30-count bottle, Rx Only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD NDC 59746-711-30

Affected NDC 59746-0711-30

Compare with the code on your package — it is the most precise check available.

Drug: Clomipramine

Recalling firm
Jubilant Cadista Pharmaceuticals, Inc.
NDC code
59746-711-30
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0104-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Clomipramine recalls

See all
Class II · Moderate risk

clomiPRAMINE Hydrochloride

cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 16714-851-01 D-0154-2026
Class II · Moderate risk

clomiPRAMINE Hydrochloride

cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 16714-850-01 D-0153-2026
Class II · Moderate risk

clomiPRAMINE Hydrochloride

cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 16714-849-01 D-0152-2026
Class II · Moderate risk

clomiPRAMINE Hydrochloride Capsules USP 25 mg

Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during retention sample testing at expiry.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-492-01 D-0537-2025
Class II · Moderate risk

clomiPRAMINE hydrochloride Capsules USP

Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during 18-month long term stability study.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-492-01 D-0377-2025

Other recalls by Jubilant Cadista Pharmaceuticals, Inc.

All 2020 recalls
Class II · Moderate risk

Irbesartan Tablets

Failed Dissolution Specifications

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-447-90 D-1294-2022
Class II · Moderate risk

Irbesartan Tablets

Failed dissolution specifications.

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-448-90 D-1293-2022